Drugs / rHBsAg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00426712 | Jan 2006 → Mar 2008 | hepatitis B virus infection | Dynavax Technologies Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHBsAg | “Recombinant Hepatitis B Virus Surface Antigen (rHBsAg) Co-administered With Dynavax Immunostimulatory Phosphorothioate Oligodeoxyribonucleotide (1018 ISS)” NCT00426712 ↗ |
| Known as | Recombinant Hepatitis B Virus Surface Antigen | “Recombinant Hepatitis B Virus Surface Antigen (rHBsAg)” NCT00426712 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Hepatitis B Virus Surface Antigen (rHBsAg)” NCT00426712 ↗ |
| Route | Intramuscular | “Intramuscular (IM) injections on Day 0, Week 4 and Week 24” NCT00426712 ↗ |